Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Future applications of FGF/FGFR inhibitors in cancer.

Ghedini GC, Ronca R, Presta M, Giacomini A.

Expert Rev Anticancer Ther. 2018 Sep;18(9):861-872. doi: 10.1080/14737140.2018.1491795. Epub 2018 Jul 2. Review.

PMID:
29936878
2.

Long pentraxin 3: A novel multifaceted player in cancer.

Giacomini A, Ghedini GC, Presta M, Ronca R.

Biochim Biophys Acta Rev Cancer. 2018 Jan;1869(1):53-63. doi: 10.1016/j.bbcan.2017.11.004. Epub 2017 Nov 23. Review.

PMID:
29175552
3.

Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.

Castagnoli L, Ghedini GC, Koschorke A, Triulzi T, Dugo M, Gasparini P, Casalini P, Palladini A, Iezzi M, Lamolinara A, Lollini PL, Nanni P, Chiodoni C, Tagliabue E, Pupa SM.

Oncogene. 2017 Mar 23;36(12):1721-1732. doi: 10.1038/onc.2016.338. Epub 2016 Sep 19.

4.

Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.

Castagnoli L, Iezzi M, Ghedini GC, Ciravolo V, Marzano G, Lamolinara A, Zappasodi R, Gasparini P, Campiglio M, Amici A, Chiodoni C, Palladini A, Lollini PL, Triulzi T, Menard S, Nanni P, Tagliabue E, Pupa SM.

Cancer Res. 2014 Nov 1;74(21):6248-59. doi: 10.1158/0008-5472.CAN-14-0983. Epub 2014 Aug 27.

5.

Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target.

Zappasodi R, Bongarzone I, Ghedini GC, Castagnoli L, Cabras AD, Messina A, Tortoreto M, Tripodo C, Magni M, Carlo-Stella C, Gianni AM, Pupa SM, Di Nicola M.

Blood. 2011 Oct 20;118(16):4421-30. doi: 10.1182/blood-2011-06-364570. Epub 2011 Aug 22.

PMID:
21860023
6.

Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy.

Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, Morelli D, Villa A, Della Mina P, Menard S, Filipazzi P, Rivoltini L, Tagliabue E, Pupa SM.

J Cell Physiol. 2012 Feb;227(2):658-67. doi: 10.1002/jcp.22773.

PMID:
21465472
7.

Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.

Zappasodi R, Pupa SM, Ghedini GC, Bongarzone I, Magni M, Cabras AD, Colombo MP, Carlo-Stella C, Gianni AM, Di Nicola M.

Cancer Res. 2010 Nov 15;70(22):9062-72. doi: 10.1158/0008-5472.CAN-10-1825. Epub 2010 Sep 30.

8.

Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.

Ghedini GC, Ciravolo V, Tortoreto M, Giuffrè S, Bianchi F, Campiglio M, Mortarino M, Figini M, Coliva A, Carcangiu ML, Zambetti M, Piazza T, Ferrini S, Ménard S, Tagliabue E, Pupa SM.

J Cell Physiol. 2010 Oct;225(1):256-65. doi: 10.1002/jcp.22257.

PMID:
20506359

Supplemental Content

Loading ...
Support Center